At a glance
- Angiotensin 1-7 (TXA127) is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 2,448 publications mentioning it, including 24 randomized controlled trials and 1,173 animal-only studies.
- ClinicalTrials.gov lists 43 registered studies testing it (4 active).
- FDA’s adverse event system (FAERS) has no reports mentioning it.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Angiotensin-(1-7) and ACE2 in maternal obesity: a pathway to protection.
- Angiotensin-(1-7) attenuates collagen-induced arthritis and suppresses ferroptosis in THP-1-derived macrophages: involvement of p53/SLC7A11 signaling.
- Lower circulating angiotensinogen levels across ACLD stages are associated with hepatic dysfunction and mortality.
- HPLC-Quantified Styphnolobium japonicum Extract Attenuates Microglial Inflammation and Hypertension in L-NAME-Treated Rats.
- Angiotensin (1-7)-based Proteomimetic Polymers as Topicals for the Remediation and Repair of the Cornea following Injury.
- Differential expression and clinical significance of angiotensin (1-7)/Ang II and Elabela/Ang II ratios in patients with acute heart failure and type I cardiorenal syndrome.
- The role of renin-angiotensin system modulation in the pathophysiology of neuropsychiatric disorders.
- The Role of the Renin-Angiotensin-Aldosterone System in Hypertensive Emergencies.
- Exploring the Association of Angiotensin-(1-7) with Left Ventricular Mass Index in Youth with Hereditary Hypophosphatemia: A Pilot Study.
- Mechanistic Assessment of Norepinephrine Therapy versus Angiotensin-II in Septic Shock (MANTRA): Study Protocol for a multicenter randomized trial.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 43
- Active
- 4
- With posted results
- 7
Conditions studied
Show 33 more studies
All 43 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
No FAERS reports mention this peptide.
Change history
No changes since monitoring began on October 30, 2026.